J. Lynn Lynn Rutkowski

Dr. J. Lynn Lynn Rutkowski


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
PSPawel Stocki
Pawel Stocki
JSJaroslaw Szary
Jaroslaw Szary
CRCharlotte L. M. Rasmussen
Charlotte L. M. Rasmussen
MDMykhaylo Demydchuk
Mykhaylo Demydchuk
LNLeandra Northall
Leandra Northall
JRJ. Lynn Lynn Rutkowski
J. Lynn Lynn Rutkowski
Transfer across the blood‐brain barrier (BBB) remains a significant hurdle for the development of biopharmaceuticals with therapeutic effects within the central nervous system. We established a functional selection method to identify high affinity single domain antibodies to the transferrin receptor 1 (TfR1) with efficient biotherapeutic delivery across the BBB. A synthetic phage display library based on the variable domain of new antigen receptor (VNAR) was used for in vitro selection against recombinant human TfR1 ectodomain (rh‐TfR1‐ECD) followed by in vivo selection in mouse for brain parenchyma penetrating antibodies. TXB2 VNAR was identified as a high affinity, species cross‐reactive VNAR antibody against TfR1‐ECD that does not compete with transferrin or ferritin for receptor binding. IV dosing of TXB2 when fused to human Fc domain (TXB2‐hFc) at 25 nmol/kg (1.875 mg/kg) in mice resulted in rapid binding to brain capillaries with subsequent transport into the brain parenchyma and specific uptake into TfR1‐positive neurons. Likewise, IV dosing of TXB2‐hFc fused with neurotensin (TXB2‐hFc‐NT) at 25 nmol/kg resulted in a rapid and reversible pharmacological response as measured by body temperature reduction. TXB2‐hFc did not elicit any acute adverse reactions, bind, or deplete circulating reticulocytes or reduce BBB‐expressed endogenous TfR1 in mice. There was no evidence of target‐mediated clearance or accumulation in peripheral organs except lung. In conclusion, TXB2 is a high affinity, species cross‐reactive, and brain‐selective VNAR antibody to TfR1 that rapidly crosses the BBB and exhibits a favorable pharmacokinetic and safety profile and can be readily adapted to carry a wide variety of biotherapeutics from blood to brain.

24 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ECEmily Clarke
Emily Clarke
PSPawel Stocki
Pawel Stocki
ESElizabeth H. Sinclair
Elizabeth H. Sinclair
AGAziz Gauhar
Aziz Gauhar
EFEdward J. R. Fletcher
Edward J. R. Fletcher
JRJ. Lynn Lynn Rutkowski
J. Lynn Lynn Rutkowski
Single domain shark antibodies that bind to the transferrin receptor 1 (TfR1) on brain endothelial cells have been used to shuttle antibodies and other cargos across the blood brain barrier (BBB) to the brain. For these studies the TXB4 brain shuttle was fused to a TrkB neurotrophin receptor agonist antibody. The TXB4-TrkB fusion retained potent agonist activity at its cognate receptor and after systemic administration showed a 12-fold increase in brain levels over the unmodified antibody. Only the TXB4-TrkB antibody fusion was detected within the brain and localized to TrkB positive cells in the cortex and tyrosine hydroxylase (TH) positive dopaminergic neurons in the substantia nigra pars compacta (SNc), where it was associated with activated ERK1/2 signaling. When tested in the 6-hydroxydopamine (6-OHDA) mouse model of Parkinson’s disease (PD), TXB4-TrkB, but not the unmodified antibody, completely prevented the 6-OHDA induced death of TH positive neurons in the SNc. In conclusion, the fusion of the TXB4 brain shuttle allows a TrkB agonist antibody to reach neuroprotective concentrations in the brain parenchyma following systemic administration.

1 July 2016 in Molecular Immunology
Verified
Journal Article
Closed access
JHJulien Häsler
Julien Häsler
MFMartin F. Flajnik
Martin F. Flajnik
GWGareth Williams
Gareth Williams
FWFrank S. Walsh
Frank S. Walsh
JRJ. Lynn Lynn Rutkowski
J. Lynn Lynn Rutkowski

23 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PSPawel Stocki
Pawel Stocki
JSJaroslaw Szary
Jaroslaw Szary
MDMykhaylo Demydchuk
Mykhaylo Demydchuk
LNLeandra Northall
Leandra Northall
CRCharlotte Rasmussen
Charlotte Rasmussen
JRJ. Lynn Lynn Rutkowski
J. Lynn Lynn Rutkowski
Since the delivery of biologic drugs to the brain is greatly hampered by the existence of the blood–brain barrier (BBB), brain shuttles are being developed to enhance therapeutic efficacy. As we have previously shown, efficient and selective brain delivery was achieved with TXB2, a cross-species reactive, anti-TfR1 VNAR antibody. To further explore the limits of brain penetration, we conducted restricted randomization of the CDR3 loop, followed by phage display to identify improved TXB2 variants. The variants were screened for brain penetration in mice using a 25 nmol/kg (1.875 mg/kg) dose and a single 18 h timepoint. A higher kinetic association rate to TfR1 correlated with improved brain penetration in vivo. The most potent variant, TXB4, showed a 3.6-fold improvement over TXB2, which had on average 14-fold higher brain levels when compared to an isotype control. Like TXB2, TXB4 retained brain specificity with parenchymal penetration and no accumulation in other organs. When fused with a neurotensin (NT) payload, it led to a rapid drop in body temperature upon transport across the BBB. We also showed that fusion of TXB4 to four therapeutic antibodies (anti-CD20, anti-EGFRvIII, anti-PD-L1 and anti-BACE1) improved their brain exposure between 14- to 30-fold. In summary, we enhanced the potency of parental TXB2 brain shuttle and gained a critical mechanistic understanding of brain delivery mediated by the VNAR anti-TfR1 antibody.

28 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
PSPawel Stocki
Pawel Stocki
JSJaroslaw M Szary
Jaroslaw M Szary
CRCharlotte Rasmussen
Charlotte Rasmussen
MDMykhaylo Demydchuk
Mykhaylo Demydchuk
LNLeandra Northall
Leandra Northall
KWKrzysztof B Wicher
Krzysztof B Wicher
Transfer across the blood-brain barrier (BBB) remains a significant hurdle for the development of biopharmaceuticals with therapeutic effects within the central nervous system. We established a functional selection method to identify high-affinity single domain antibodies to the transferrin receptor 1 (TfR1) with efficient biotherapeutic delivery across the BBB. Methods: A synthetic phage display library based on the variable domain of new antigen receptor (VNAR) was used for in vitro selection against recombinant human TfR1 ectodomain (rh-TfR1-ECD) followed by in vivo selection in mouse for brain parenchyma penetrating antibodies. Phage formatted VNARs cross-reactive to recombinant human and mouse TfR1-ECD were fused to Fc domain of human IgG1 (hFc) and tested for TfR1-ECD binding by ELISA and surface plasmon resonance. The pharmacokinetics and biodistribution of VNAR-hFcs were studied in mice by ELISA and immunolabeling following intravenous (IV) injection and cardiac perfusion. Functional activity was measured by body temperature reduction following the IV injection of neurotensin fused to a TXB2-hFc (TXB2-hFc-NT). Results: TXB2 was identified as a high-affinity, species cross-reactive VNAR antibody against TfR1-ECD, that does not to compete with transferrin or ferritin for receptor binding. IV dosing of TXB2-hFc at 25 nmol/kg (1.875 mg/kg) in mice resulted in rapid binding to brain capillaries with subsequent transport into the brain parenchyma and specific uptake into TfR1-positive neurons. Likewise, IV dosing of TXB2-hFc-NT at 25 nmol/kg resulted in a rapid and reversible pharmacological response as measured by body temperature reduction. TXB2-hFc did not elicit any acute adverse reactions, bind or deplete circulating reticulocytes or reduce BBB-expressed endogenous TfR1 in mice. There was no evidence of target-mediated clearance or accumulation in peripheral organs except lung. Conclusions: A species cross-reactive and brain-selective VNAR antibody to TfR1 was identified by a combination of in vitro and in vivo phage selection. As a high-affinity, bivalent Fc fusion protein, TXB2 rapidly crossed the BBB and exhibited a favorable pharmacokinetic and safety profile and can be readily adapted to carry a wide variety of biotherapeutics from blood to brain.

12 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ECEmily Clarke
Emily Clarke
LSLiz Sinclair
Liz Sinclair
EFEdward J R Fletcher
Edward J R Fletcher
AKAlicja Krawczun-Rygmaczewska
Alicja Krawczun-Rygmaczewska
SDSusan Duty
Susan Duty
FWFrank S. Walsh
Frank S. Walsh
Single domain shark antibodies that bind to the transferrin receptor 1 (TfR1) on brain endothelial cells can be used to shuttle antibodies and other cargos across the blood brain barrier (BBB). We have fused one of these (TXB4) to differing regions of TrkB and TrkC neurotrophin receptor agonist antibodies (AAb) and determined the effect on agonist activity, brain accumulation and engagement with neurons in the mouse brain following systemic administration. The TXB4-TrkB and TXB4-TrkC fusion proteins retain agonist activity at their respective neurotrophin receptors and in contrast to their parental AAb they rapidly accumulate in the brain reaching nM levels following a single IV injection. Following SC administration, the most active TrkB fusion protein, TXB4-TrkB 1 , associates with and activates ERK1/2 signalling in TrkB positive cells in the cortex and tyrosine hydroxylase (TH) positive dopaminergic neurons in the substantia nigra pars compacta (SNc). When tested in the 6-hydroxydopamine (6-OHDA) mouse model of Parkinson’s disease (PD) TXB4-TrkB 1 , but not the parental TrkB AAb or a TXB4-TrkC 1 fusion protein, completely prevented the 6-OHDA induced death of TH positive neurons in the SNc. In conclusion, the fusion of the TXB4 TfR1 binding module allows a TrkB AAb to reach neuroprotective concentrations in the brain parenchyma following systemic administration.